Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis.

Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, Dagfinrud H, Dijkmans B, Dougados M, Emery P, Geher P, Hammoudeh M, Inman RD, Jongkees M, Khan MA, Kiltz U, Kvien T, Leirisalo-Repo M, Maksymowych WP, Olivieri I, Pavelka K, Sieper J, Stanislawska-Biernat E, Wendling D, Ozgocmen S, van Drogen C, van Royen B, van der Heijde D.

Ann Rheum Dis. 2011 Jun;70(6):896-904. doi: 10.1136/ard.2011.151027.

2.

[ASAS/EULAR recommendations for the management of ankylosing spondylitis : evaluation of the 2010 update in the German-speaking area].

Kiltz U, Sieper J, Braun J.

Z Rheumatol. 2013 Feb;72(1):71-80. doi: 10.1007/s00393-012-1071-z. German.

PMID:
23223873
3.

First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis.

Braun J, Davis J, Dougados M, Sieper J, van der Linden S, van der Heijde D; ASAS Working Group.

Ann Rheum Dis. 2006 Mar;65(3):316-20. Epub 2005 Aug 11.

4.

ASAS/EULAR recommendations for the management of ankylosing spondylitis.

Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC Jr, Dijkmans B, Dougados M, Géher P, Inman RD, Khan MA, Kvien TK, Leirisalo-Repo M, Olivieri I, Pavelka K, Sieper J, Stucki G, Sturrock RD, van der Linden S, Wendling D, Böhm H, van Royen BJ, Braun J; 'ASsessment in AS' international working group; European League Against Rheumatism.

Ann Rheum Dis. 2006 Apr;65(4):442-52. Epub 2005 Aug 26.

5.

First update of the current evidence for the management of ankylosing spondylitis with non-pharmacological treatment and non-biologic drugs: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis.

van den Berg R, Baraliakos X, Braun J, van der Heijde D.

Rheumatology (Oxford). 2012 Aug;51(8):1388-96. doi: 10.1093/rheumatology/kes066. Epub 2012 Apr 17. Review.

PMID:
22513148
6.

[Recommendations for the management of ankylosing spodylitis after ASAS/EULAR. Evaluation in the German language area].

Braun J, Zochling J, Märker-Hermann E, Stucki G, Böhm H, Rudwaleit M, Zeidler H, Sieper J.

Z Rheumatol. 2006 Dec;65(8):728-42. German.

PMID:
17119900
7.

Update of the literature review on treatment with biologics as a basis for the first update of the ASAS/EULAR management recommendations of ankylosing spondylitis.

Baraliakos X, van den Berg R, Braun J, van der Heijde D.

Rheumatology (Oxford). 2012 Aug;51(8):1378-87. doi: 10.1093/rheumatology/kes026. Epub 2012 Mar 16. Review.

PMID:
22427410
8.
9.

An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis.

Pham T, Landewé R, van der Linden S, Dougados M, Sieper J, Braun J, Davis J, Rudwaleit M, Collantes E, Burgos-Vargas R, Edmonds J, Olivieri I, van der Horst-Bruinsma I, Mielants H, Stone M, Emery P, van der Heijde D.

Ann Rheum Dis. 2006 Dec;65(12):1620-5. Epub 2006 Feb 7.

10.

2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis.

van der Heijde D, Sieper J, Maksymowych WP, Dougados M, Burgos-Vargas R, Landewé R, Rudwaleit M, Braun J; Assessment of SpondyloArthritis international Society.

Ann Rheum Dis. 2011 Jun;70(6):905-8. doi: 10.1136/ard.2011.151563.

PMID:
21540200
11.

2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis.

van der Heijde D, Ramiro S, Landewé R, Baraliakos X, Van den Bosch F, Sepriano A, Regel A, Ciurea A, Dagfinrud H, Dougados M, van Gaalen F, Géher P, van der Horst-Bruinsma I, Inman RD, Jongkees M, Kiltz U, Kvien TK, Machado PM, Marzo-Ortega H, Molto A, Navarro-Compàn V, Ozgocmen S, Pimentel-Santos FM, Reveille J, Rudwaleit M, Sieper J, Sampaio-Barros P, Wiek D, Braun J.

Ann Rheum Dis. 2017 Jun;76(6):978-991. doi: 10.1136/annrheumdis-2016-210770. Epub 2017 Jan 13. Review.

PMID:
28087505
12.

International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis.

Braun J, Pham T, Sieper J, Davis J, van der Linden S, Dougados M, van der Heijde D; ASAS Working Group.

Ann Rheum Dis. 2003 Sep;62(9):817-24. Review.

13.

EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update.

Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJ, Kvien TK, Dougados M, Radner H, Atzeni F, Primdahl J, Södergren A, Wallberg Jonsson S, van Rompay J, Zabalan C, Pedersen TR, Jacobsson L, de Vlam K, Gonzalez-Gay MA, Semb AG, Kitas GD, Smulders YM, Szekanecz Z, Sattar N, Symmons DP, Nurmohamed MT.

Ann Rheum Dis. 2017 Jan;76(1):17-28. doi: 10.1136/annrheumdis-2016-209775. Epub 2016 Oct 3. Review.

PMID:
27697765
14.
15.

Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update.

Pham T, Fautrel B, Dernis E, Goupille P, Guillemin F, Le Loët X, Ravaud P, Claudepierre P, Miceli-Richard C, de Bandt M, Breban M, Maillefert JF, Masson C, Saraux A, Schaeverbeke T, Wendling D, Mariette X, Combe B; Club Rhumatismes et Inflammation (CRI/SFR).

Joint Bone Spine. 2007 Dec;74(6):638-46. Epub 2007 Nov 8.

PMID:
18065252
16.

ASAS/EULAR recommendations for the management of ankylosing spondylitis: the patient version.

Kiltz U, van der Heijde D, Mielants H, Feldtkeller E, Braun J; PARE/EULAR patient initiative group.

Ann Rheum Dis. 2009 Sep;68(9):1381-6. doi: 10.1136/ard.2008.096073. Epub 2008 Oct 17.

PMID:
18930993
17.

[Ankylosing spondylitis].

Braun J.

MMW Fortschr Med. 2009 Nov 19;151(47):79-83; quiz 84. German. No abstract available.

PMID:
20037984
18.

Current therapeutics for spondyloarthritis.

Toussirot É.

Expert Opin Pharmacother. 2011 Nov;12(16):2469-77. doi: 10.1517/14656566.2011.604313. Review.

PMID:
21988214
19.

[ASAS recommendations on the use of TNF inhibitors for patients with axial spondyloarthritis : evaluation of the 2010 update in the German-speaking area].

Kiltz U, Sieper J, Braun J.

Z Rheumatol. 2013 Feb;72(1):81-8. doi: 10.1007/s00393-012-1089-2. German.

PMID:
23338704
20.

Developments and current pharmacotherapeutic recommendations for ankylosing spondylitis.

Zochling J, Braun J.

Expert Opin Pharmacother. 2006 May;7(7):869-83. Review.

PMID:
16634710

Supplemental Content

Support Center